65. Hussein MA: Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma. Oncologist7(suppl 1):20-29, 2002.

66. Barlogie B, Desikan R, Eddlemon P, et al.: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 98:492-494, 2001.

67. Offidani M, Corvatta L, Marconi M, et al.: Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma. Hematol J 5:312-317,

0 0

Post a comment